The clinical spectrum of laryngeal dystonia includes dystonic cough: Observations of a large series

Movement Disorders

Volumn 29, Issue 6, 2014, Pages 729-735

  Payne, Susannah ^a   Tisch, Stephen ^b   Cole, Ian ^b   Brake, Helen ^b   Rough, Judy ^b   Darveniza, Paul ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Botulinum toxin; Dystonic cough; Laryngeal dystonia

Indexed keywords

BOTULINUM TOXIN; NEUROLEPTIC AGENT; NEUROTOXIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; BREATHING; CHILD; COUGHING; DISEASE EXACERBATION; DRINKING; DYSPHAGIA; DYSPHONIA; EATING; FAMILY HISTORY; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HICCUP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; ONSET AGE; PAIN; PRIORITY JOURNAL; SCHOOL CHILD; SNEEZING; SPASMODIC DYSPHONIA; STRIDOR; TORTICOLLIS; TREATMENT FAILURE; TREATMENT OUTCOME; VOCAL CORD PARALYSIS; CLASSIFICATION; COMPLICATION; COUGH; DYSTONIA; LARYNGEAL DISEASES; OBSERVATION; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BOTULINUM TOXINS; COUGH; DYSTONIA; FEMALE; HUMANS; LARYNGEAL DISEASES; LINEAR MODELS; MALE; MIDDLE AGED; NEUROTOXINS; OBSERVATION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84899937084     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25865     Document Type: Article

References (27)

1. Tarsy D, Simon D. Dystonia. N Engl J Med 2006;355:818-829.
2. Ludlow C, Naunton R, Sectary S, Schulz G, Hallett M. Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia. Neurology 1988;38:1220-1220.
3. Simonyan K, Ludlow C. Abnormal structure-function relationship in spasmodic dysphonia. Cereb Cortex 2012;22:417-425.
4. Tanner K, Roy N, Merrill R, Sauder C, Houtz D, Smith M. Spasmodic dysphonia: onset, course, socioemotional effects, and treatment response. Ann Otol Rhinol Laryngol 2011;120:465-473.
5. Blitzer A, Brin M, Stewart C. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope 1998;108:1435-1441.
6. Blitzer A. Spasmodic dysphonia and botulinum toxin: experience from the largest treatment series. Eur J Neurol 2010;17:28-30.
7. Blitzer A, Brin M. Laryngeal dystonia: a series with botulinum toxin therapy. Ann Otol Rhinol Laryngol 1991;100:85-89.
8. Grillone G, Annino D Jr, Blitzer A, Brin M, Saint-Hilaire M. Treatment of adductor laryngeal breathing dystonia with botulinum toxin type A. Laryngoscope 1994;104:30-32.
9. Zwirner P, Dressler D, Kruse E. Spasmodic laryngeal dyspnea: a rare manifestation of laryngeal dystonia. Eur Arch Otorhinolaryngol 1997;254:242-245.
10. Koufman J, Block C. Differential diagnosis of paradoxical vocal fold movement. Am J Speech Lang Pathol 2008;17:327-334.
11. Tisch S, Brake H, Law M, Cole I, Darveniza P. Spasmodic dysphonia: clinical features and effects of botulinum toxin therapy in 169 patients-an Australian experience. J Clin Neurosci 2003;10:434-438.
12. Blitzer A, Sulica L. Botulinum toxin: basic science and clinical uses in otolaryngology. Laryngoscope 2001;111:218-226.
13. Thurman L, Klitzke CA. Voice education and health care for young voices. In: Benninger MS, Jacobson BH, Johnson AF, editors. Vocal Arts Medicine: The Care and Prevention of Professional Voice Disorders. New York: Thieme Medical Publishers; 1994; 226-268.
14. Hallett M, Benecke R, Blitzer A, Comella CL. Treatment of focal dystonias with botulinum neurotoxin. Toxicon 2009;54:628-633.
15. Blitzer A, Brin M, Fahn S, Lovelace R. Clinical and laboratory characteristics of focal laryngeal dystonia: study of 110 cases. Laryngoscope 1988;98:636-640.
16. Chu M, Lieser J, Sinacori J. Use of botulinum toxin type A for chronic cough: a neuropathic model. Arch Otolaryngol Head Neck Surg 2010;136:447-452.
17. Feve A, Angelard B, Guily J. Laryngeal tardive dyskinesia. J Neurol 1995;242:455-459.
18. Lundy D, Lu F, Casiano R, Xue J. The effect of patient factors on response outcomes to Botox treatment of spasmodic dysphonia. J Voice 1998;12:460-466.
19. Galardi G, Guerriero R, Amadio S, et al. Sporadic failure of botulinum toxin treatment in usually responsive patients with adductor spasmodic dysphonia. Neurol Sci 2001;22:303-306.
20. Brin M, Blitzer A, Fahn S, Lovelace R, Gould W. Adductor laryngeal dystonia (spastic dysphonia): treatment with local injections of botulinum toxin (Botox). Mov Disord 1989;4:287-296.
21. Zwirner P, Murry T, Swenson M, Woodson G. Effects of botulinum toxin therapy in patients with adductor spasmodic dysphonia: acoustic, aerodynamic, and videoendoscopic findings. Laryngoscope 1992;102:400-406.
22. Park J, Simpson L, Anderson T, Sataloff R. Immunologic characterization of spasmodic dysphonia patients who develop resistance to botulinum toxin. J Voice 2003;17:255-264.
23. Smith M, Ford C. Resistance to botulinum toxin injections for spasmodic dysphonia. Arch Otolaryngol Head Neck Surg 2000;126:533-535.
24. Schweinfurth J, Billante M, Courey M. Risk factors and demographics in patients with spasmodic dysphonia. Laryngoscope 2002;112:220-223.
25. Kipps C, Fung V, Grattan-Smith P, de Moore G, Morris J. Movement disorder emergencies. Mov Disord 2005;20:322-334.
26. Hood S, Orr K, Bennett L, Davies S. Severe laryngeal dystonia in a patient receiving zuclopenthixol "Acuphase" and fluoxetine. Australas Psychiatry 2010;18:174-176.
27. Russell S, Hennes H, Herson K, Stremski E. Upper airway compromise in acute chlorpromazine ingestion. Am J Emerg Med 1996;14 467-468.